Clearmind Medicine (CMND) Prepares Human Clinical Trials for its Psychedelic Treatment for Alcohol Abuse

Clearmind Medicine (CMND) Prepares Human Clinical Trials for its Psychedelic Treatment for Alcohol Abuse
They call it a miracle. What if this novel psychedelic could be the solution to alcoholism? Recent up-list to the NASDAQ with a 1.29M share float.

Hello everyone,

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMN) is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems.

Current price $4.61/share (as of market close 11-24-22)

There are quite a few companies in the biopharma sector working with psychedelics to develop compounds to treat mental illnesses. I want to talk about CMND because I think they have developed a novel compound and are approaching treatment in a different way.

Recent structural change at CMND:

The company implemented a 1-for-30 reverse stock split, which was effective at 5:30 p.m. on September 30, 2022. CMND also uplisted to the NASDAQ on November 15, 2022, and on November 17th the company announced it closed a public offering of 1,153,847 common shares at a price to the public of $6.50 per share for gross proceeds of $7.5 million. It was a busy couple of weeks for the company.

The lead product at CMND is called CMND-100, a compound based upon the MEAI (5-Methoxy-2-aminoindane) psychoactive molecule. The company believes that MEAI could be used in treatment for Alcohol Abuse Disorder (AUD), binge eating, depression, psychotherapy, along with other mental health issues and binging disorders. The company’s goal is to develop CMND-100 as an orally self-administered product.

CMND is about to enter a human clinical trial for the treatment of AUD. I’m not going to quote a litany of statistics about alcohol abuse. We all know what the studies will say and most of us have personally been touched by the negativity of an alcohol abuse situation.

While CMND will be the first company to look for FDA approval for MSEI, it has been used by some as a recreational psychedelic drug and here are a couple comments made by those users:

“It’s the ‘enough’ switch. It signals to the brain that it is satisfied, that it wants nothing.”

“MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages.”

“After consuming it, I feel intense but controlled euphoria. Now the idea of drinking alcohol seems repulsive—as does eating bar food.”

I urge you to watch this short video detailing the development of MEAI, with comments from the company team and testimonials.

I also want you to consider this quote from CMND CEO Dr. Adi Suloff-Shani, “what we see is so phenomenal that I have to be very optimistic about how psychedelics can actually completely change the way we treat mental health issues today.”

On Wednesday this week, CMND announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100. The produced batches will be used in the Company’s upcoming first human clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD). This step marks the initial move into clinical trials.

The Company’s intellectual portfolio currently consists of seven patent families that include 8 granted patents and 15 pending applications. The portfolio spans a wide range of jurisdictions including the US, Europe, India, and China.

In the interest of transparency CMND has stated how they plan to use the proceeds from their recent public offering.

$1.5 million to advance the formulation and clinical development efforts in their MEAI patented compounds.
$1.0 million to complete the pre-IND enabling studies and IND submission.
$3.5 million to complete their planned Phase I/IIa studies.
Remainder for working capital & general corporate purposes & possible in-licensing of intellectual property for new product candidates.

CMND statistics:

FYE is October 31st – MRQ is July 31, 2022
Outstanding shares                       2.5M (after last week’s public offering)
Shares in float                                TBD (after last week’s public offering)
Cash (mrq)                                      $817K (+ $7.5M raised last week)
Market cap                                     $11.5M

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build the portfolio.

The Traders News Group

Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell your information to anyone.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails.

The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy Policy

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice.

All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated up to twenty thousand dollars cash via bank wire for our distributed opinions this week on cmnd. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.

TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.

TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.

Copyright © 2022 Traders News Source LLC, All rights reserved.